GE HealthCare, Medis Medical Imaging Team Up for Non-Invasive Coronary Assessment

GE HealthCare and cardiac imaging software company Medis Medical Imaging announced they’ve begun a collaboration focused on diagnosing and treating coronary artery disease (CAD).
 
The duo said they’ll work together to further develop and commercialize the Medis Quantitative Flow Ratio (Medis QFR). Medis QFR is a non-invasive way to assess cardiac physiology. It will be used as part of GE HealthCare’s interventional cardiology portfolio, built around the Allia Platform.
 
Usually, diagnosing suspected CAD requires invasive coronary angiography to help determine the disease’s severity. Then, then angiogram will be visually interpreted to decide whether percutaneous coronary intervention (PCI) is needed and to determine where or which lesion to treat to restore blood flow.
 
GE HealthCare’s partnership with Medis hopes to bring Medis QFR to the clinic as a non-invasive, image-based diagnostic strategy to assess coronary artery physiology and treat CAD. A recent study showed a QFR-guided approach for PCI lesion selection improved two-year outcomes. This included reducing myocardial infarction and  ischemia-driven revascularization compared to standard angiography guidance alone.
 
Medis’ QFR delivers image-based coronary obstruction physiology based on only angiography imaging analysis. If treatment is necessary, QFR tech can help to select the ultimate lesions(s) to treat and build the correct treatment plan for a balloon or stent-based PCI. The analysis can occur in real-time, while the patient is on the table, and be displayed on a large monitor in the cath lab.
 
“We continue to see an evolution in how clinicians work to treat cardiovascular disease and want to give clinicians the tools, along with the flexibility and adaptability, they need to enable better outcomes for their patients,” said Arnaud Marie, GM for Global Intervention at GE HealthCare. “In the assessment of coronary artery disease, QFR represents a significant advancement in how efficiently it can provide critical insights. We’re excited to collaborate with Medis Medical Imaging to add innovative, non-invasive, image-based QFR to our portfolio of offerings around our Allia IGS platform to streamline the experience for clinicians and help us to deliver on our vision for the future image-guided therapy.”
 
“We are absolutely delighted to be taking this next step with GE HealthCare, a fellow leader in the interventional cardiology domain,” added Maya Barley, CEO of Medis Medical Imaging. “Building on Medis QFR’s decade of AI research, customer-focused product development, clinical evidence generation and business development, we are excited to be able to further accelerate our efforts around Medis QFR to enable more hospitals and clinicians to apply physiology in day-to-day interventional practice a part of best-practice clinical care—making this technology more accessible and available to patients than ever before.”